Global PD-1&PD-L1 Immunotherapy Market Insights, Forecast to 2029
This report presents an overview of global market for PD-1&PD-L1 Immunotherapy, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of PD-1&PD-L1 Immunotherapy, also provides the sales of main regions and countries. Highlights of the upcoming market potential for PD-1&PD-L1 Immunotherapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PD-1&PD-L1 Immunotherapy sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global PD-1&PD-L1 Immunotherapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for PD-1&PD-L1 Immunotherapy sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including AstraZeneca Plc, BeiGene, Ltd., Bristol-Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly & Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Innovent Biologics, Inc. and Jiangsu HengRui Medicine Co., Ltd., etc.
By Company
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of PD-1&PD-L1 Immunotherapy in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of PD-1&PD-L1 Immunotherapy manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: China by type, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-1&PD-L1 Immunotherapy sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
This report researches the key producers of PD-1&PD-L1 Immunotherapy, also provides the sales of main regions and countries. Highlights of the upcoming market potential for PD-1&PD-L1 Immunotherapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PD-1&PD-L1 Immunotherapy sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2023. Identification of the major stakeholders in the global PD-1&PD-L1 Immunotherapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2029. Evaluation and forecast the market size for PD-1&PD-L1 Immunotherapy sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including AstraZeneca Plc, BeiGene, Ltd., Bristol-Myers Squibb Company, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly & Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Innovent Biologics, Inc. and Jiangsu HengRui Medicine Co., Ltd., etc.
By Company
- AstraZeneca Plc
- BeiGene, Ltd.
- Bristol-Myers Squibb Company
- Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
- Eli Lilly & Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Innovent Biologics, Inc.
- Jiangsu HengRui Medicine Co., Ltd.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi S.A.
- PD-1 Inhibitors
- PD-L1 Inhibitors
- Non-Small Cell Lung Cancer
- Esophageal Cancer
- Urothelial Carcinoma
- Hepatocellular Carcinoma
- Small Cell Lung Cancer
- Others
- US & Canada
- U.S.
- Canada
- China
- Asia (excluding China)
- Japan
- South Korea
- China Taiwan
- Southeast Asia
- India
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Middle East, Africa, Latin America
- Brazil
- Mexico
- Turkey
- Israel
- GCC Countries
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of PD-1&PD-L1 Immunotherapy in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of PD-1&PD-L1 Immunotherapy manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: China by type, by application sales and revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-1&PD-L1 Immunotherapy sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 STUDY COVERAGE
1.1 PD-1&PD-L1 Immunotherapy Product Introduction
1.2 Market by Type
1.2.1 Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 Market by Application
1.3.1 Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Non-Small Cell Lung Cancer
1.3.3 Esophageal Cancer
1.3.4 Urothelial Carcinoma
1.3.5 Hepatocellular Carcinoma
1.3.6 Small Cell Lung Cancer
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global PD-1&PD-L1 Immunotherapy Sales Estimates and Forecasts 2018-2029
2.2 Global PD-1&PD-L1 Immunotherapy Revenue by Region
2.2.1 Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global PD-1&PD-L1 Immunotherapy Revenue by Region (2018-2023)
2.2.3 Global PD-1&PD-L1 Immunotherapy Revenue by Region (2024-2029)
2.2.4 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2018-2029)
2.3 Global PD-1&PD-L1 Immunotherapy Sales Estimates and Forecasts 2018-2029
2.4 Global PD-1&PD-L1 Immunotherapy Sales by Region
2.4.1 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global PD-1&PD-L1 Immunotherapy Sales by Region (2018-2023)
2.4.3 Global PD-1&PD-L1 Immunotherapy Sales by Region (2024-2029)
2.4.4 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 COMPETITION BY MANUFACTURES
3.1 Global PD-1&PD-L1 Immunotherapy Sales by Manufacturers
3.1.1 Global PD-1&PD-L1 Immunotherapy Sales by Manufacturers (2018-2023)
3.1.2 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of PD-1&PD-L1 Immunotherapy in 2022
3.2 Global PD-1&PD-L1 Immunotherapy Revenue by Manufacturers
3.2.1 Global PD-1&PD-L1 Immunotherapy Revenue by Manufacturers (2018-2023)
3.2.2 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by PD-1&PD-L1 Immunotherapy Revenue in 2022
3.3 Global Key Players of PD-1&PD-L1 Immunotherapy, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global PD-1&PD-L1 Immunotherapy Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global PD-1&PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Product Offered and Application
3.8 Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 MARKET SIZE BY TYPE
4.1 Global PD-1&PD-L1 Immunotherapy Sales by Type
4.1.1 Global PD-1&PD-L1 Immunotherapy Historical Sales by Type (2018-2023)
4.1.2 Global PD-1&PD-L1 Immunotherapy Forecasted Sales by Type (2024-2029)
4.1.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
4.2 Global PD-1&PD-L1 Immunotherapy Revenue by Type
4.2.1 Global PD-1&PD-L1 Immunotherapy Historical Revenue by Type (2018-2023)
4.2.2 Global PD-1&PD-L1 Immunotherapy Forecasted Revenue by Type (2024-2029)
4.2.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
4.3 Global PD-1&PD-L1 Immunotherapy Price by Type
4.3.1 Global PD-1&PD-L1 Immunotherapy Price by Type (2018-2023)
4.3.2 Global PD-1&PD-L1 Immunotherapy Price Forecast by Type (2024-2029)
5 MARKET SIZE BY APPLICATION
5.1 Global PD-1&PD-L1 Immunotherapy Sales by Application
5.1.1 Global PD-1&PD-L1 Immunotherapy Historical Sales by Application (2018-2023)
5.1.2 Global PD-1&PD-L1 Immunotherapy Forecasted Sales by Application (2024-2029)
5.1.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
5.2 Global PD-1&PD-L1 Immunotherapy Revenue by Application
5.2.1 Global PD-1&PD-L1 Immunotherapy Historical Revenue by Application (2018-2023)
5.2.2 Global PD-1&PD-L1 Immunotherapy Forecasted Revenue by Application (2024-2029)
5.2.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
5.3 Global PD-1&PD-L1 Immunotherapy Price by Application
5.3.1 Global PD-1&PD-L1 Immunotherapy Price by Application (2018-2023)
5.3.2 Global PD-1&PD-L1 Immunotherapy Price Forecast by Application (2024-2029)
6 US & CANADA
6.1 US & Canada PD-1&PD-L1 Immunotherapy Market Size by Type
6.1.1 US & Canada PD-1&PD-L1 Immunotherapy Sales by Type (2018-2029)
6.1.2 US & Canada PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2029)
6.2 US & Canada PD-1&PD-L1 Immunotherapy Market Size by Application
6.2.1 US & Canada PD-1&PD-L1 Immunotherapy Sales by Application (2018-2029)
6.2.2 US & Canada PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2029)
6.3 US & Canada PD-1&PD-L1 Immunotherapy Market Size by Country
6.3.1 US & Canada PD-1&PD-L1 Immunotherapy Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada PD-1&PD-L1 Immunotherapy Sales by Country (2018-2029)
6.3.3 US & Canada PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 EUROPE
7.1 Europe PD-1&PD-L1 Immunotherapy Market Size by Type
7.1.1 Europe PD-1&PD-L1 Immunotherapy Sales by Type (2018-2029)
7.1.2 Europe PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2029)
7.2 Europe PD-1&PD-L1 Immunotherapy Market Size by Application
7.2.1 Europe PD-1&PD-L1 Immunotherapy Sales by Application (2018-2029)
7.2.2 Europe PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2029)
7.3 Europe PD-1&PD-L1 Immunotherapy Market Size by Country
7.3.1 Europe PD-1&PD-L1 Immunotherapy Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe PD-1&PD-L1 Immunotherapy Sales by Country (2018-2029)
7.3.3 Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 CHINA
8.1 China PD-1&PD-L1 Immunotherapy Market Size
8.1.1 China PD-1&PD-L1 Immunotherapy Sales (2018-2029)
8.1.2 China PD-1&PD-L1 Immunotherapy Revenue (2018-2029)
8.2 China PD-1&PD-L1 Immunotherapy Market Size by Application
8.2.1 China PD-1&PD-L1 Immunotherapy Sales by Application (2018-2029)
8.2.2 China PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia PD-1&PD-L1 Immunotherapy Market Size by Type
9.1.1 Asia PD-1&PD-L1 Immunotherapy Sales by Type (2018-2029)
9.1.2 Asia PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2029)
9.2 Asia PD-1&PD-L1 Immunotherapy Market Size by Application
9.2.1 Asia PD-1&PD-L1 Immunotherapy Sales by Application (2018-2029)
9.2.2 Asia PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2029)
9.3 Asia PD-1&PD-L1 Immunotherapy Sales by Region
9.3.1 Asia PD-1&PD-L1 Immunotherapy Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia PD-1&PD-L1 Immunotherapy Revenue by Region (2018-2029)
9.3.3 Asia PD-1&PD-L1 Immunotherapy Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 MIDDLE EAST, AFRICA AND LATIN AMERICA
10.1 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Market Size by Type
10.1.1 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Market Size by Application
10.2.1 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Country
10.3.1 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 COMPANY PROFILES
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Company Information
11.1.2 AstraZeneca Plc Overview
11.1.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AstraZeneca Plc Recent Developments
11.2 BeiGene, Ltd.
11.2.1 BeiGene, Ltd. Company Information
11.2.2 BeiGene, Ltd. Overview
11.2.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 BeiGene, Ltd. Recent Developments
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Information
11.3.2 Bristol-Myers Squibb Company Overview
11.3.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bristol-Myers Squibb Company Recent Developments
11.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
11.4.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
11.4.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Overview
11.4.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments
11.5 Eli Lilly & Company
11.5.1 Eli Lilly & Company Company Information
11.5.2 Eli Lilly & Company Overview
11.5.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Eli Lilly & Company Recent Developments
11.6 F. Hoffmann-La Roche Ltd
11.6.1 F. Hoffmann-La Roche Ltd Company Information
11.6.2 F. Hoffmann-La Roche Ltd Overview
11.6.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 F. Hoffmann-La Roche Ltd Recent Developments
11.7 GlaxoSmithKline plc
11.7.1 GlaxoSmithKline plc Company Information
11.7.2 GlaxoSmithKline plc Overview
11.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 GlaxoSmithKline plc Recent Developments
11.8 Innovent Biologics, Inc.
11.8.1 Innovent Biologics, Inc. Company Information
11.8.2 Innovent Biologics, Inc. Overview
11.8.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Innovent Biologics, Inc. Recent Developments
11.9 Jiangsu HengRui Medicine Co., Ltd.
11.9.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
11.9.2 Jiangsu HengRui Medicine Co., Ltd. Overview
11.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments
11.10 Merck & Co., Inc.
11.10.1 Merck & Co., Inc. Company Information
11.10.2 Merck & Co., Inc. Overview
11.10.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Merck & Co., Inc. Recent Developments
11.11 Novartis AG
11.11.1 Novartis AG Company Information
11.11.2 Novartis AG Overview
11.11.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.11.4 Novartis AG PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Novartis AG Recent Developments
11.12 Pfizer Inc.
11.12.1 Pfizer Inc. Company Information
11.12.2 Pfizer Inc. Overview
11.12.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.12.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Pfizer Inc. Recent Developments
11.13 Regeneron Pharmaceuticals Inc.
11.13.1 Regeneron Pharmaceuticals Inc. Company Information
11.13.2 Regeneron Pharmaceuticals Inc. Overview
11.13.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.13.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Regeneron Pharmaceuticals Inc. Recent Developments
11.14 Sanofi S.A.
11.14.1 Sanofi S.A. Company Information
11.14.2 Sanofi S.A. Overview
11.14.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.14.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Sanofi S.A. Recent Developments
12 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
12.1 PD-1&PD-L1 Immunotherapy Industry Chain Analysis
12.2 PD-1&PD-L1 Immunotherapy Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 PD-1&PD-L1 Immunotherapy Production Mode & Process
12.4 PD-1&PD-L1 Immunotherapy Sales and Marketing
12.4.1 PD-1&PD-L1 Immunotherapy Sales Channels
12.4.2 PD-1&PD-L1 Immunotherapy Distributors
12.5 PD-1&PD-L1 Immunotherapy Customers
13 MARKET DYNAMICS
13.1 PD-1&PD-L1 Immunotherapy Industry Trends
13.2 PD-1&PD-L1 Immunotherapy Market Drivers
13.3 PD-1&PD-L1 Immunotherapy Market Challenges
13.4 PD-1&PD-L1 Immunotherapy Market Restraints
14 KEY FINDINGS IN THE GLOBAL PD-1&PD-L1 IMMUNOTHERAPY STUDY
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
1.1 PD-1&PD-L1 Immunotherapy Product Introduction
1.2 Market by Type
1.2.1 Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 Market by Application
1.3.1 Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Non-Small Cell Lung Cancer
1.3.3 Esophageal Cancer
1.3.4 Urothelial Carcinoma
1.3.5 Hepatocellular Carcinoma
1.3.6 Small Cell Lung Cancer
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global PD-1&PD-L1 Immunotherapy Sales Estimates and Forecasts 2018-2029
2.2 Global PD-1&PD-L1 Immunotherapy Revenue by Region
2.2.1 Global PD-1&PD-L1 Immunotherapy Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global PD-1&PD-L1 Immunotherapy Revenue by Region (2018-2023)
2.2.3 Global PD-1&PD-L1 Immunotherapy Revenue by Region (2024-2029)
2.2.4 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2018-2029)
2.3 Global PD-1&PD-L1 Immunotherapy Sales Estimates and Forecasts 2018-2029
2.4 Global PD-1&PD-L1 Immunotherapy Sales by Region
2.4.1 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global PD-1&PD-L1 Immunotherapy Sales by Region (2018-2023)
2.4.3 Global PD-1&PD-L1 Immunotherapy Sales by Region (2024-2029)
2.4.4 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 COMPETITION BY MANUFACTURES
3.1 Global PD-1&PD-L1 Immunotherapy Sales by Manufacturers
3.1.1 Global PD-1&PD-L1 Immunotherapy Sales by Manufacturers (2018-2023)
3.1.2 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of PD-1&PD-L1 Immunotherapy in 2022
3.2 Global PD-1&PD-L1 Immunotherapy Revenue by Manufacturers
3.2.1 Global PD-1&PD-L1 Immunotherapy Revenue by Manufacturers (2018-2023)
3.2.2 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by PD-1&PD-L1 Immunotherapy Revenue in 2022
3.3 Global Key Players of PD-1&PD-L1 Immunotherapy, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global PD-1&PD-L1 Immunotherapy Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global PD-1&PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Product Offered and Application
3.8 Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 MARKET SIZE BY TYPE
4.1 Global PD-1&PD-L1 Immunotherapy Sales by Type
4.1.1 Global PD-1&PD-L1 Immunotherapy Historical Sales by Type (2018-2023)
4.1.2 Global PD-1&PD-L1 Immunotherapy Forecasted Sales by Type (2024-2029)
4.1.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
4.2 Global PD-1&PD-L1 Immunotherapy Revenue by Type
4.2.1 Global PD-1&PD-L1 Immunotherapy Historical Revenue by Type (2018-2023)
4.2.2 Global PD-1&PD-L1 Immunotherapy Forecasted Revenue by Type (2024-2029)
4.2.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
4.3 Global PD-1&PD-L1 Immunotherapy Price by Type
4.3.1 Global PD-1&PD-L1 Immunotherapy Price by Type (2018-2023)
4.3.2 Global PD-1&PD-L1 Immunotherapy Price Forecast by Type (2024-2029)
5 MARKET SIZE BY APPLICATION
5.1 Global PD-1&PD-L1 Immunotherapy Sales by Application
5.1.1 Global PD-1&PD-L1 Immunotherapy Historical Sales by Application (2018-2023)
5.1.2 Global PD-1&PD-L1 Immunotherapy Forecasted Sales by Application (2024-2029)
5.1.3 Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
5.2 Global PD-1&PD-L1 Immunotherapy Revenue by Application
5.2.1 Global PD-1&PD-L1 Immunotherapy Historical Revenue by Application (2018-2023)
5.2.2 Global PD-1&PD-L1 Immunotherapy Forecasted Revenue by Application (2024-2029)
5.2.3 Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
5.3 Global PD-1&PD-L1 Immunotherapy Price by Application
5.3.1 Global PD-1&PD-L1 Immunotherapy Price by Application (2018-2023)
5.3.2 Global PD-1&PD-L1 Immunotherapy Price Forecast by Application (2024-2029)
6 US & CANADA
6.1 US & Canada PD-1&PD-L1 Immunotherapy Market Size by Type
6.1.1 US & Canada PD-1&PD-L1 Immunotherapy Sales by Type (2018-2029)
6.1.2 US & Canada PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2029)
6.2 US & Canada PD-1&PD-L1 Immunotherapy Market Size by Application
6.2.1 US & Canada PD-1&PD-L1 Immunotherapy Sales by Application (2018-2029)
6.2.2 US & Canada PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2029)
6.3 US & Canada PD-1&PD-L1 Immunotherapy Market Size by Country
6.3.1 US & Canada PD-1&PD-L1 Immunotherapy Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada PD-1&PD-L1 Immunotherapy Sales by Country (2018-2029)
6.3.3 US & Canada PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 EUROPE
7.1 Europe PD-1&PD-L1 Immunotherapy Market Size by Type
7.1.1 Europe PD-1&PD-L1 Immunotherapy Sales by Type (2018-2029)
7.1.2 Europe PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2029)
7.2 Europe PD-1&PD-L1 Immunotherapy Market Size by Application
7.2.1 Europe PD-1&PD-L1 Immunotherapy Sales by Application (2018-2029)
7.2.2 Europe PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2029)
7.3 Europe PD-1&PD-L1 Immunotherapy Market Size by Country
7.3.1 Europe PD-1&PD-L1 Immunotherapy Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe PD-1&PD-L1 Immunotherapy Sales by Country (2018-2029)
7.3.3 Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 CHINA
8.1 China PD-1&PD-L1 Immunotherapy Market Size
8.1.1 China PD-1&PD-L1 Immunotherapy Sales (2018-2029)
8.1.2 China PD-1&PD-L1 Immunotherapy Revenue (2018-2029)
8.2 China PD-1&PD-L1 Immunotherapy Market Size by Application
8.2.1 China PD-1&PD-L1 Immunotherapy Sales by Application (2018-2029)
8.2.2 China PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2029)
9 ASIA (EXCLUDING CHINA)
9.1 Asia PD-1&PD-L1 Immunotherapy Market Size by Type
9.1.1 Asia PD-1&PD-L1 Immunotherapy Sales by Type (2018-2029)
9.1.2 Asia PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2029)
9.2 Asia PD-1&PD-L1 Immunotherapy Market Size by Application
9.2.1 Asia PD-1&PD-L1 Immunotherapy Sales by Application (2018-2029)
9.2.2 Asia PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2029)
9.3 Asia PD-1&PD-L1 Immunotherapy Sales by Region
9.3.1 Asia PD-1&PD-L1 Immunotherapy Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia PD-1&PD-L1 Immunotherapy Revenue by Region (2018-2029)
9.3.3 Asia PD-1&PD-L1 Immunotherapy Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 MIDDLE EAST, AFRICA AND LATIN AMERICA
10.1 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Market Size by Type
10.1.1 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Market Size by Application
10.2.1 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Country
10.3.1 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 COMPANY PROFILES
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc Company Information
11.1.2 AstraZeneca Plc Overview
11.1.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AstraZeneca Plc Recent Developments
11.2 BeiGene, Ltd.
11.2.1 BeiGene, Ltd. Company Information
11.2.2 BeiGene, Ltd. Overview
11.2.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 BeiGene, Ltd. Recent Developments
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Information
11.3.2 Bristol-Myers Squibb Company Overview
11.3.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bristol-Myers Squibb Company Recent Developments
11.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
11.4.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
11.4.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Overview
11.4.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments
11.5 Eli Lilly & Company
11.5.1 Eli Lilly & Company Company Information
11.5.2 Eli Lilly & Company Overview
11.5.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Eli Lilly & Company Recent Developments
11.6 F. Hoffmann-La Roche Ltd
11.6.1 F. Hoffmann-La Roche Ltd Company Information
11.6.2 F. Hoffmann-La Roche Ltd Overview
11.6.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 F. Hoffmann-La Roche Ltd Recent Developments
11.7 GlaxoSmithKline plc
11.7.1 GlaxoSmithKline plc Company Information
11.7.2 GlaxoSmithKline plc Overview
11.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 GlaxoSmithKline plc Recent Developments
11.8 Innovent Biologics, Inc.
11.8.1 Innovent Biologics, Inc. Company Information
11.8.2 Innovent Biologics, Inc. Overview
11.8.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Innovent Biologics, Inc. Recent Developments
11.9 Jiangsu HengRui Medicine Co., Ltd.
11.9.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
11.9.2 Jiangsu HengRui Medicine Co., Ltd. Overview
11.9.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments
11.10 Merck & Co., Inc.
11.10.1 Merck & Co., Inc. Company Information
11.10.2 Merck & Co., Inc. Overview
11.10.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Merck & Co., Inc. Recent Developments
11.11 Novartis AG
11.11.1 Novartis AG Company Information
11.11.2 Novartis AG Overview
11.11.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.11.4 Novartis AG PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Novartis AG Recent Developments
11.12 Pfizer Inc.
11.12.1 Pfizer Inc. Company Information
11.12.2 Pfizer Inc. Overview
11.12.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.12.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Pfizer Inc. Recent Developments
11.13 Regeneron Pharmaceuticals Inc.
11.13.1 Regeneron Pharmaceuticals Inc. Company Information
11.13.2 Regeneron Pharmaceuticals Inc. Overview
11.13.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.13.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Regeneron Pharmaceuticals Inc. Recent Developments
11.14 Sanofi S.A.
11.14.1 Sanofi S.A. Company Information
11.14.2 Sanofi S.A. Overview
11.14.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Price, Revenue and Gross Margin (2018-2023)
11.14.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Sanofi S.A. Recent Developments
12 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
12.1 PD-1&PD-L1 Immunotherapy Industry Chain Analysis
12.2 PD-1&PD-L1 Immunotherapy Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 PD-1&PD-L1 Immunotherapy Production Mode & Process
12.4 PD-1&PD-L1 Immunotherapy Sales and Marketing
12.4.1 PD-1&PD-L1 Immunotherapy Sales Channels
12.4.2 PD-1&PD-L1 Immunotherapy Distributors
12.5 PD-1&PD-L1 Immunotherapy Customers
13 MARKET DYNAMICS
13.1 PD-1&PD-L1 Immunotherapy Industry Trends
13.2 PD-1&PD-L1 Immunotherapy Market Drivers
13.3 PD-1&PD-L1 Immunotherapy Market Challenges
13.4 PD-1&PD-L1 Immunotherapy Market Restraints
14 KEY FINDINGS IN THE GLOBAL PD-1&PD-L1 IMMUNOTHERAPY STUDY
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
LIST OF TABLES
Table 1. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of PD-1 Inhibitors
Table 3. Major Manufacturers of PD-L1 Inhibitors
Table 4. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2018-2023)
Table 9. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2024-2029)
Table 10. Global PD-1&PD-L1 Immunotherapy Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global PD-1&PD-L1 Immunotherapy Sales by Region (2018-2023) & (Units)
Table 12. Global PD-1&PD-L1 Immunotherapy Sales by Region (2024-2029) & (Units)
Table 13. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2018-2023)
Table 14. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2024-2029)
Table 15. Global PD-1&PD-L1 Immunotherapy Sales by Manufacturers (2018-2023) & (Units)
Table 16. Global PD-1&PD-L1 Immunotherapy Sales Share by Manufacturers (2018-2023)
Table 17. Global PD-1&PD-L1 Immunotherapy Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global PD-1&PD-L1 Immunotherapy Revenue Share by Manufacturers (2018-2023)
Table 19. Global Key Players of PD-1&PD-L1 Immunotherapy, Industry Ranking, 2021 VS 2022 VS 2023
Table 20. PD-1&PD-L1 Immunotherapy Price by Manufacturers 2018-2023 (US$/Unit)
Table 21. Global PD-1&PD-L1 Immunotherapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global PD-1&PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1&PD-L1 Immunotherapy as of 2022)
Table 23. Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Product Offered and Application
Table 25. Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 28. Global PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 29. Global PD-1&PD-L1 Immunotherapy Sales Share by Type (2018-2023)
Table 30. Global PD-1&PD-L1 Immunotherapy Sales Share by Type (2024-2029)
Table 31. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 32. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global PD-1&PD-L1 Immunotherapy Revenue Share by Type (2018-2023)
Table 34. Global PD-1&PD-L1 Immunotherapy Revenue Share by Type (2024-2029)
Table 35. PD-1&PD-L1 Immunotherapy Price by Type (2018-2023) & (US$/Unit)
Table 36. Global PD-1&PD-L1 Immunotherapy Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 38. Global PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 39. Global PD-1&PD-L1 Immunotherapy Sales Share by Application (2018-2023)
Table 40. Global PD-1&PD-L1 Immunotherapy Sales Share by Application (2024-2029)
Table 41. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global PD-1&PD-L1 Immunotherapy Revenue Share by Application (2018-2023)
Table 44. Global PD-1&PD-L1 Immunotherapy Revenue Share by Application (2024-2029)
Table 45. PD-1&PD-L1 Immunotherapy Price by Application (2018-2023) & (US$/Unit)
Table 46. Global PD-1&PD-L1 Immunotherapy Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 48. US & Canada PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 49. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 50. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 52. US & Canada PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 53. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 54. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2023) & (US$ Million)
Table 57. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada PD-1&PD-L1 Immunotherapy Sales by Country (2018-2023) & (Units)
Table 59. US & Canada PD-1&PD-L1 Immunotherapy Sales by Country (2024-2029) & (Units)
Table 60. Europe PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 61. Europe PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 62. Europe PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 63. Europe PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 65. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 66. Europe PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 67. Europe PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2023) & (US$ Million)
Table 70. Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2018-2023) & (Units)
Table 72. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2024-2029) & (Units)
Table 73. China PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 74. China PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 75. China PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 76. China PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 77. China PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 78. China PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 79. China PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 80. China PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 82. Asia PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 83. Asia PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 84. Asia PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 86. Asia PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 87. Asia PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 88. Asia PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia PD-1&PD-L1 Immunotherapy Revenue by Region (2018-2023) & (US$ Million)
Table 91. Asia PD-1&PD-L1 Immunotherapy Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia PD-1&PD-L1 Immunotherapy Sales by Region (2018-2023) & (Units)
Table 93. Asia PD-1&PD-L1 Immunotherapy Sales by Region (2024-2029) & (Units)
Table 94. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 95. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 96. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 97. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 99. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 100. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 101. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2023) & (Units)
Table 106. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2024-2029) & (Units)
Table 107. AstraZeneca Plc Company Information
Table 108. AstraZeneca Plc Description and Major Businesses
Table 109. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. AstraZeneca Plc Recent Developments
Table 112. BeiGene, Ltd. Company Information
Table 113. BeiGene, Ltd. Description and Major Businesses
Table 114. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. BeiGene, Ltd. Recent Developments
Table 117. Bristol-Myers Squibb Company Company Information
Table 118. Bristol-Myers Squibb Company Description and Major Businesses
Table 119. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Bristol-Myers Squibb Company Recent Developments
Table 122. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
Table 123. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Description and Major Businesses
Table 124. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments
Table 127. Eli Lilly & Company Company Information
Table 128. Eli Lilly & Company Description and Major Businesses
Table 129. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 130. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Eli Lilly & Company Recent Developments
Table 132. F. Hoffmann-La Roche Ltd Company Information
Table 133. F. Hoffmann-La Roche Ltd Description and Major Businesses
Table 134. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 135. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. F. Hoffmann-La Roche Ltd Recent Developments
Table 137. GlaxoSmithKline plc Company Information
Table 138. GlaxoSmithKline plc Description and Major Businesses
Table 139. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 140. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. GlaxoSmithKline plc Recent Developments
Table 142. Innovent Biologics, Inc. Company Information
Table 143. Innovent Biologics, Inc. Description and Major Businesses
Table 144. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 145. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Innovent Biologics, Inc. Recent Developments
Table 147. Jiangsu HengRui Medicine Co., Ltd. Company Information
Table 148. Jiangsu HengRui Medicine Co., Ltd. Description and Major Businesses
Table 149. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 150. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Jiangsu HengRui Medicine Co., Ltd. Recent Developments
Table 152. Merck & Co., Inc. Company Information
Table 153. Merck & Co., Inc. Description and Major Businesses
Table 154. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 155. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Merck & Co., Inc. Recent Developments
Table 157. Novartis AG Company Information
Table 158. Novartis AG Description and Major Businesses
Table 159. Novartis AG PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 160. Novartis AG PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Novartis AG Recent Developments
Table 162. Pfizer Inc. Company Information
Table 163. Pfizer Inc. Description and Major Businesses
Table 164. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 165. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Pfizer Inc. Recent Developments
Table 167. Regeneron Pharmaceuticals Inc. Company Information
Table 168. Regeneron Pharmaceuticals Inc. Description and Major Businesses
Table 169. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 170. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Regeneron Pharmaceuticals Inc. Recent Developments
Table 172. Sanofi S.A. Company Information
Table 173. Sanofi S.A. Description and Major Businesses
Table 174. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 175. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Sanofi S.A. Recent Developments
Table 177. Key Raw Materials Lists
Table 178. Raw Materials Key Suppliers Lists
Table 179. PD-1&PD-L1 Immunotherapy Distributors List
Table 180. PD-1&PD-L1 Immunotherapy Customers List
Table 181. PD-1&PD-L1 Immunotherapy Market Trends
Table 182. PD-1&PD-L1 Immunotherapy Market Drivers
Table 183. PD-1&PD-L1 Immunotherapy Market Challenges
Table 184. PD-1&PD-L1 Immunotherapy Market Restraints
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
Table 1. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of PD-1 Inhibitors
Table 3. Major Manufacturers of PD-L1 Inhibitors
Table 4. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global PD-1&PD-L1 Immunotherapy Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2018-2023)
Table 9. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2024-2029)
Table 10. Global PD-1&PD-L1 Immunotherapy Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global PD-1&PD-L1 Immunotherapy Sales by Region (2018-2023) & (Units)
Table 12. Global PD-1&PD-L1 Immunotherapy Sales by Region (2024-2029) & (Units)
Table 13. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2018-2023)
Table 14. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2024-2029)
Table 15. Global PD-1&PD-L1 Immunotherapy Sales by Manufacturers (2018-2023) & (Units)
Table 16. Global PD-1&PD-L1 Immunotherapy Sales Share by Manufacturers (2018-2023)
Table 17. Global PD-1&PD-L1 Immunotherapy Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global PD-1&PD-L1 Immunotherapy Revenue Share by Manufacturers (2018-2023)
Table 19. Global Key Players of PD-1&PD-L1 Immunotherapy, Industry Ranking, 2021 VS 2022 VS 2023
Table 20. PD-1&PD-L1 Immunotherapy Price by Manufacturers 2018-2023 (US$/Unit)
Table 21. Global PD-1&PD-L1 Immunotherapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global PD-1&PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1&PD-L1 Immunotherapy as of 2022)
Table 23. Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Product Offered and Application
Table 25. Global Key Manufacturers of PD-1&PD-L1 Immunotherapy, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 28. Global PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 29. Global PD-1&PD-L1 Immunotherapy Sales Share by Type (2018-2023)
Table 30. Global PD-1&PD-L1 Immunotherapy Sales Share by Type (2024-2029)
Table 31. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 32. Global PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global PD-1&PD-L1 Immunotherapy Revenue Share by Type (2018-2023)
Table 34. Global PD-1&PD-L1 Immunotherapy Revenue Share by Type (2024-2029)
Table 35. PD-1&PD-L1 Immunotherapy Price by Type (2018-2023) & (US$/Unit)
Table 36. Global PD-1&PD-L1 Immunotherapy Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 38. Global PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 39. Global PD-1&PD-L1 Immunotherapy Sales Share by Application (2018-2023)
Table 40. Global PD-1&PD-L1 Immunotherapy Sales Share by Application (2024-2029)
Table 41. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global PD-1&PD-L1 Immunotherapy Revenue Share by Application (2018-2023)
Table 44. Global PD-1&PD-L1 Immunotherapy Revenue Share by Application (2024-2029)
Table 45. PD-1&PD-L1 Immunotherapy Price by Application (2018-2023) & (US$/Unit)
Table 46. Global PD-1&PD-L1 Immunotherapy Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 48. US & Canada PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 49. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 50. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 52. US & Canada PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 53. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 54. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2023) & (US$ Million)
Table 57. US & Canada PD-1&PD-L1 Immunotherapy Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada PD-1&PD-L1 Immunotherapy Sales by Country (2018-2023) & (Units)
Table 59. US & Canada PD-1&PD-L1 Immunotherapy Sales by Country (2024-2029) & (Units)
Table 60. Europe PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 61. Europe PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 62. Europe PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 63. Europe PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 65. Europe PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 66. Europe PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 67. Europe PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2023) & (US$ Million)
Table 70. Europe PD-1&PD-L1 Immunotherapy Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2018-2023) & (Units)
Table 72. Europe PD-1&PD-L1 Immunotherapy Sales by Country (2024-2029) & (Units)
Table 73. China PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 74. China PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 75. China PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 76. China PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 77. China PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 78. China PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 79. China PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 80. China PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 82. Asia PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 83. Asia PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 84. Asia PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 86. Asia PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 87. Asia PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 88. Asia PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia PD-1&PD-L1 Immunotherapy Revenue by Region (2018-2023) & (US$ Million)
Table 91. Asia PD-1&PD-L1 Immunotherapy Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia PD-1&PD-L1 Immunotherapy Sales by Region (2018-2023) & (Units)
Table 93. Asia PD-1&PD-L1 Immunotherapy Sales by Region (2024-2029) & (Units)
Table 94. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Type (2018-2023) & (Units)
Table 95. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Type (2024-2029) & (Units)
Table 96. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Type (2018-2023) & (US$ Million)
Table 97. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Application (2018-2023) & (Units)
Table 99. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Application (2024-2029) & (Units)
Table 100. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Application (2018-2023) & (US$ Million)
Table 101. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Country (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2018-2023) & (Units)
Table 106. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales by Country (2024-2029) & (Units)
Table 107. AstraZeneca Plc Company Information
Table 108. AstraZeneca Plc Description and Major Businesses
Table 109. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. AstraZeneca Plc Recent Developments
Table 112. BeiGene, Ltd. Company Information
Table 113. BeiGene, Ltd. Description and Major Businesses
Table 114. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. BeiGene, Ltd. Recent Developments
Table 117. Bristol-Myers Squibb Company Company Information
Table 118. Bristol-Myers Squibb Company Description and Major Businesses
Table 119. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Bristol-Myers Squibb Company Recent Developments
Table 122. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
Table 123. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Description and Major Businesses
Table 124. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments
Table 127. Eli Lilly & Company Company Information
Table 128. Eli Lilly & Company Description and Major Businesses
Table 129. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 130. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Eli Lilly & Company Recent Developments
Table 132. F. Hoffmann-La Roche Ltd Company Information
Table 133. F. Hoffmann-La Roche Ltd Description and Major Businesses
Table 134. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 135. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. F. Hoffmann-La Roche Ltd Recent Developments
Table 137. GlaxoSmithKline plc Company Information
Table 138. GlaxoSmithKline plc Description and Major Businesses
Table 139. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 140. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. GlaxoSmithKline plc Recent Developments
Table 142. Innovent Biologics, Inc. Company Information
Table 143. Innovent Biologics, Inc. Description and Major Businesses
Table 144. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 145. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Innovent Biologics, Inc. Recent Developments
Table 147. Jiangsu HengRui Medicine Co., Ltd. Company Information
Table 148. Jiangsu HengRui Medicine Co., Ltd. Description and Major Businesses
Table 149. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 150. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Jiangsu HengRui Medicine Co., Ltd. Recent Developments
Table 152. Merck & Co., Inc. Company Information
Table 153. Merck & Co., Inc. Description and Major Businesses
Table 154. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 155. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Merck & Co., Inc. Recent Developments
Table 157. Novartis AG Company Information
Table 158. Novartis AG Description and Major Businesses
Table 159. Novartis AG PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 160. Novartis AG PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Novartis AG Recent Developments
Table 162. Pfizer Inc. Company Information
Table 163. Pfizer Inc. Description and Major Businesses
Table 164. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 165. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. Pfizer Inc. Recent Developments
Table 167. Regeneron Pharmaceuticals Inc. Company Information
Table 168. Regeneron Pharmaceuticals Inc. Description and Major Businesses
Table 169. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 170. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Regeneron Pharmaceuticals Inc. Recent Developments
Table 172. Sanofi S.A. Company Information
Table 173. Sanofi S.A. Description and Major Businesses
Table 174. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 175. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. Sanofi S.A. Recent Developments
Table 177. Key Raw Materials Lists
Table 178. Raw Materials Key Suppliers Lists
Table 179. PD-1&PD-L1 Immunotherapy Distributors List
Table 180. PD-1&PD-L1 Immunotherapy Customers List
Table 181. PD-1&PD-L1 Immunotherapy Market Trends
Table 182. PD-1&PD-L1 Immunotherapy Market Drivers
Table 183. PD-1&PD-L1 Immunotherapy Market Challenges
Table 184. PD-1&PD-L1 Immunotherapy Market Restraints
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. PD-1&PD-L1 Immunotherapy Product Picture
Figure 2. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global PD-1&PD-L1 Immunotherapy Market Share by Type in 2022 & 2029
Figure 4. PD-1 Inhibitors Product Picture
Figure 5. PD-L1 Inhibitors Product Picture
Figure 6. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global PD-1&PD-L1 Immunotherapy Market Share by Application in 2022 & 2029
Figure 8. Non-Small Cell Lung Cancer
Figure 9. Esophageal Cancer
Figure 10. Urothelial Carcinoma
Figure 11. Hepatocellular Carcinoma
Figure 12. Small Cell Lung Cancer
Figure 13. Others
Figure 14. PD-1&PD-L1 Immunotherapy Report Years Considered
Figure 15. Global PD-1&PD-L1 Immunotherapy Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global PD-1&PD-L1 Immunotherapy Revenue 2018-2029 (US$ Million)
Figure 17. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 18. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2018-2029)
Figure 19. Global PD-1&PD-L1 Immunotherapy Sales 2018-2029 ((Units)
Figure 20. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2018-2029)
Figure 21. US & Canada PD-1&PD-L1 Immunotherapy Sales YoY (2018-2029) & (Units)
Figure 22. US & Canada PD-1&PD-L1 Immunotherapy Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Europe PD-1&PD-L1 Immunotherapy Sales YoY (2018-2029) & (Units)
Figure 24. Europe PD-1&PD-L1 Immunotherapy Revenue YoY (2018-2029) & (US$ Million)
Figure 25. China PD-1&PD-L1 Immunotherapy Sales YoY (2018-2029) & (Units)
Figure 26. China PD-1&PD-L1 Immunotherapy Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Asia (excluding China) PD-1&PD-L1 Immunotherapy Sales YoY (2018-2029) & (Units)
Figure 28. Asia (excluding China) PD-1&PD-L1 Immunotherapy Revenue YoY (2018-2029) & (US$ Million)
Figure 29. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales YoY (2018-2029) & (Units)
Figure 30. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue YoY (2018-2029) & (US$ Million)
Figure 31. The PD-1&PD-L1 Immunotherapy Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 32. The Top 5 and 10 Largest Manufacturers of PD-1&PD-L1 Immunotherapy in the World: Market Share by PD-1&PD-L1 Immunotherapy Revenue in 2022
Figure 33. Global PD-1&PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 35. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 36. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 37. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 39. US & Canada PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 40. US & Canada PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 41. US & Canada PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 42. US & Canada PD-1&PD-L1 Immunotherapy Revenue Share by Country (2018-2029)
Figure 43. US & Canada PD-1&PD-L1 Immunotherapy Sales Share by Country (2018-2029)
Figure 44. U.S. PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 45. Canada PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 46. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 47. Europe PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 48. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 49. Europe PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 50. Europe PD-1&PD-L1 Immunotherapy Revenue Share by Country (2018-2029)
Figure 51. Europe PD-1&PD-L1 Immunotherapy Sales Share by Country (2018-2029)
Figure 52. Germany PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 53. France PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 54. U.K. PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 55. Italy PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 56. Russia PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 57. China PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 58. China PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 59. China PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 60. China PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 61. Asia PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 62. Asia PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 63. Asia PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 64. Asia PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 65. Asia PD-1&PD-L1 Immunotherapy Revenue Share by Region (2018-2029)
Figure 66. Asia PD-1&PD-L1 Immunotherapy Sales Share by Region (2018-2029)
Figure 67. Japan PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 68. South Korea PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 69. China Taiwan PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 70. Southeast Asia PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 71. India PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 72. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 74. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 76. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue Share by Country (2018-2029)
Figure 77. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales Share by Country (2018-2029)
Figure 78. Brazil PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 79. Mexico PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 80. Turkey PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 81. Israel PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 82. GCC Countries PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 83. PD-1&PD-L1 Immunotherapy Value Chain
Figure 84. PD-1&PD-L1 Immunotherapy Production Process
Figure 85. Channels of Distribution
Figure 86. Distributors Profiles
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
Figure 1. PD-1&PD-L1 Immunotherapy Product Picture
Figure 2. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global PD-1&PD-L1 Immunotherapy Market Share by Type in 2022 & 2029
Figure 4. PD-1 Inhibitors Product Picture
Figure 5. PD-L1 Inhibitors Product Picture
Figure 6. Global PD-1&PD-L1 Immunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global PD-1&PD-L1 Immunotherapy Market Share by Application in 2022 & 2029
Figure 8. Non-Small Cell Lung Cancer
Figure 9. Esophageal Cancer
Figure 10. Urothelial Carcinoma
Figure 11. Hepatocellular Carcinoma
Figure 12. Small Cell Lung Cancer
Figure 13. Others
Figure 14. PD-1&PD-L1 Immunotherapy Report Years Considered
Figure 15. Global PD-1&PD-L1 Immunotherapy Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global PD-1&PD-L1 Immunotherapy Revenue 2018-2029 (US$ Million)
Figure 17. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 18. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Region (2018-2029)
Figure 19. Global PD-1&PD-L1 Immunotherapy Sales 2018-2029 ((Units)
Figure 20. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2018-2029)
Figure 21. US & Canada PD-1&PD-L1 Immunotherapy Sales YoY (2018-2029) & (Units)
Figure 22. US & Canada PD-1&PD-L1 Immunotherapy Revenue YoY (2018-2029) & (US$ Million)
Figure 23. Europe PD-1&PD-L1 Immunotherapy Sales YoY (2018-2029) & (Units)
Figure 24. Europe PD-1&PD-L1 Immunotherapy Revenue YoY (2018-2029) & (US$ Million)
Figure 25. China PD-1&PD-L1 Immunotherapy Sales YoY (2018-2029) & (Units)
Figure 26. China PD-1&PD-L1 Immunotherapy Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Asia (excluding China) PD-1&PD-L1 Immunotherapy Sales YoY (2018-2029) & (Units)
Figure 28. Asia (excluding China) PD-1&PD-L1 Immunotherapy Revenue YoY (2018-2029) & (US$ Million)
Figure 29. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales YoY (2018-2029) & (Units)
Figure 30. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue YoY (2018-2029) & (US$ Million)
Figure 31. The PD-1&PD-L1 Immunotherapy Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 32. The Top 5 and 10 Largest Manufacturers of PD-1&PD-L1 Immunotherapy in the World: Market Share by PD-1&PD-L1 Immunotherapy Revenue in 2022
Figure 33. Global PD-1&PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 35. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 36. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 37. Global PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 38. US & Canada PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 39. US & Canada PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 40. US & Canada PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 41. US & Canada PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 42. US & Canada PD-1&PD-L1 Immunotherapy Revenue Share by Country (2018-2029)
Figure 43. US & Canada PD-1&PD-L1 Immunotherapy Sales Share by Country (2018-2029)
Figure 44. U.S. PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 45. Canada PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 46. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 47. Europe PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 48. Europe PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 49. Europe PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 50. Europe PD-1&PD-L1 Immunotherapy Revenue Share by Country (2018-2029)
Figure 51. Europe PD-1&PD-L1 Immunotherapy Sales Share by Country (2018-2029)
Figure 52. Germany PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 53. France PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 54. U.K. PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 55. Italy PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 56. Russia PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 57. China PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 58. China PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 59. China PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 60. China PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 61. Asia PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 62. Asia PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 63. Asia PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 64. Asia PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 65. Asia PD-1&PD-L1 Immunotherapy Revenue Share by Region (2018-2029)
Figure 66. Asia PD-1&PD-L1 Immunotherapy Sales Share by Region (2018-2029)
Figure 67. Japan PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 68. South Korea PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 69. China Taiwan PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 70. Southeast Asia PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 71. India PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 72. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue Market Share by Type (2018-2029)
Figure 74. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue Market Share by Application (2018-2029)
Figure 76. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Revenue Share by Country (2018-2029)
Figure 77. Middle East, Africa and Latin America PD-1&PD-L1 Immunotherapy Sales Share by Country (2018-2029)
Figure 78. Brazil PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 79. Mexico PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 80. Turkey PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 81. Israel PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 82. GCC Countries PD-1&PD-L1 Immunotherapy Revenue (2018-2029) & (US$ Million)
Figure 83. PD-1&PD-L1 Immunotherapy Value Chain
Figure 84. PD-1&PD-L1 Immunotherapy Production Process
Figure 85. Channels of Distribution
Figure 86. Distributors Profiles
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
